In comparison, in our study only a single healthy donor (of 19 tested) and no CML patients prior to vaccination (of 18 tested) had detectable IgG responses to DNAJA1; however, approximately two-thirds of patients developed anti-DNAJA1 IgG responses following K562/GVAX vaccination (Figure 5), including all four of the clinical responders having an induced antibody response after vaccination. Here, DNAJA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.